Moderna co-founder warns AI cannot replace trials soon
In short
Noubar Afeyan, Moderna’s co-founder, said AI will not soon replace clinical trials. The report said he warned against expecting AI to quickly cure diseases like cancer and called for more humility in science.
This matters for healthcare and biotech because it sets limits on what AI can do in drug development. The reporting does not say whether Moderna is changing any plan.
What the reporting says
Moderna co-founder Noubar Afeyan warned that AI cannot soon replace clinical trials, according to a publisher summary that said he cautioned against overhyping AI in disease research. He argued that scientific progress needs greater humility about what researchers understand of human physiology. The report does not name a specific company decision, product, or timeline beyond his warning.
Why it matters
Noubar Afeyan, co-founder of Moderna, warned that AI cannot quickly replace clinical trials, according to the publisher summary. He cautioned against overhyping AI’s ability to cure diseases such as cancer and said scientific progress needs greater humility about human physiology. The immediate relevance is for biotech and healthcare investors tracking AI claims in drug development. No concrete company action was reported.